HAS clarifies the framework for use of Xevudy

29 April 2022 -  After authorising early access to Xevudy (sotrovimab) as a curative treatment for COVID-19 on 6 January, HAS ...

Read more →

HAS decides in favour of reimbursement of Paxlovid

25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...

Read more →

Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients

20 April 2022 - The opinion by the Transparency Commission follows after Idefirix was granted a funded Early Access Program by ...

Read more →

Cystic fibrosis: early access granted to the Kaftrio/Kalydeco combination

29 March 2022 - The High Authority for Health has authorised early access to a first treatment for children aged 6 ...

Read more →

COVID-19: a second booster reserved for those most at risk

18 March 2022 - While the COVID-19 epidemic seems to be on the rise again after a few weeks of decline, ...

Read more →

COVID-19: early access granted to Paxlovid as a curative treatment

21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...

Read more →

Competition from biosimilars drives price reductions for biologics in the French single payer health system

6 August 2021 - France has a single payer health insurance system that has the authority to impose pharmaceutical price reductions ...

Read more →

The contribution of French patient and consumer groups to health technology assessments over a 2 year period: an observational retrospective study

22 March 2021 - In 2017, The French National Authority for Health created an open, online, systematic contribution process to enable ...

Read more →

Vaccination strategy against SARS-Cov-2

15 December 2020 - Intermediate recommendations on the methods of implementing vaccination. ...

Read more →

COVID-19 vaccine will be free of charge, 1 million inoculations set for January, French PM say

3 December 2020 - After the vaccination of an initial 1 million people in January an additional 14 million at ...

Read more →

Transparency Commission publishes its opinion on Veklury

17 September 2020 - Gilead withdrew its request for the reimbursement of remdesivir in France on 31 August 2020. ...

Read more →

France removes state funding for dementia drugs

17 January 2020 - The first country in Europe to act on concerns over limited effectiveness. ...

Read more →

As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches

3 December 2019 - As the U.S. grapples with rising costs for prescription medicines, the Trump administration has floated a proposal ...

Read more →

Could or should we use MCDA in the French HTA process?

3 December 2019 - Over the last decade, an increasing literature has been highlighting the benefits of introducing multi-criteria decision analysis ...

Read more →

French Authorities approve national reimbursement of Orkambi (lumacaftor/ivacaftor) for eligible people ages two and older with cystic fibrosis

20 November 2019 - Vertex Pharmaceuticals today announced that the French Authorities (Comité économique des produits de santé, or CEPS) ...

Read more →